Contains Waxes, Higher Fatty Acids, Higher Fatty Alcohols Patents (Class 424/502)
-
Patent number: 8685425Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-di-ethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.Type: GrantFiled: October 17, 2011Date of Patent: April 1, 2014Inventor: Tycho J. Speaker
-
Patent number: 8679546Abstract: The subject of this invention is a controlled release composition for zootechnical use. In particular, the subject of this invention is a composition comprising micro-pellets that are able to release the physiologically active substances they contain in a controlled manner. In addition, this invention refers to a procedure for preparing said composition as well as the use of said composition in the zootechnical sector.Type: GrantFiled: September 16, 2005Date of Patent: March 25, 2014Assignee: Valentini S.R.L.Inventors: Paolo Cavassini, Paolo Cicognani, Jean Antoine Meiners
-
Publication number: 20140079796Abstract: Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.Type: ApplicationFiled: September 16, 2013Publication date: March 20, 2014Applicant: McNeil-PPC, Inc.Inventors: Saumitra Bagchi, Murali K. Vuppala
-
Patent number: 8658193Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.Type: GrantFiled: June 8, 2012Date of Patent: February 25, 2014Inventor: Robert J. Greenwald
-
Patent number: 8647647Abstract: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.Type: GrantFiled: July 21, 2010Date of Patent: February 11, 2014Assignee: Aidance Skincare and Topical Solutions, LLCInventor: Perry Antelman
-
Publication number: 20140030352Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ajay Jaysingh KHOPADE, Subhas Balaram BHOWMICK, Natarajan ARULSUDAR
-
Publication number: 20140023718Abstract: There is provided a fat emulsion which has a pH of 4.5 to 6.0 and includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 0.15 times or more by mass the content of the oil ingredient, a water-soluble acid having a pKa of 4.0 to 6.0 and having a dissociable group or a salt thereof, and water; and a fat emulsion which includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 500 to 5,000 times by mass the content of the prostaglandin compound and is 0.5 to 10 times by mass the content of the oil ingredient, and water, and in which the content of a higher fatty acid is 0.06 times or less by mass the content of the lecithin.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: FUJIFILM CorporationInventors: Shigetomo TSUJIHATA, Hiroki TANISAKA, Kozo NAGATA, Yasuyuki IZUMI
-
Publication number: 20140017329Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.Type: ApplicationFiled: July 10, 2013Publication date: January 16, 2014Inventor: Shaker A. Mousa
-
Patent number: 8623412Abstract: An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders the abuse-capable compound within the matrix difficult to separate from the matrix; and a method for the preparation of a controlled release pharmaceutical composition having a reduced potential for abuse, comprising applying a pressure force to a mixture comprising a water insoluble material, and particles of a pharmaceutically active compound capable of inducing in a subject a reaction that is physiologically or psychologically detrimental if administered in an immediate release dosage form, thereby resulting in surface coated particles, and incorporating said surface coated particles into a pharmaceutical composition.Type: GrantFiled: September 23, 2003Date of Patent: January 7, 2014Assignee: Elan Pharma International LimitedInventors: Vaghefi Farid, Gary G. Liversidge, Stephen B. Ruddy, Eugene R. Cooper
-
Publication number: 20140004186Abstract: Preconcentrates comprising a fatty acid oil mixture, at least one surfactant, and at least one statin or pharmaceutically acceptable salt, hydrate, solvate, or complex thereof, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.Type: ApplicationFiled: September 8, 2011Publication date: January 2, 2014Applicant: Pronova Biopharma Norge ASInventors: Svein Olaf Hustvedt, Preben Houlberg OLesen, Gunnar Berge, Jo Erik Johnsrud Klaveness
-
Patent number: 8618081Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.Type: GrantFiled: May 4, 2011Date of Patent: December 31, 2013Assignee: Foamix Ltd.Inventors: Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz, Irakliy Papiashvili
-
Patent number: 8613956Abstract: Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15% by weight fatty acid moieties with carbon chain lengths of C18 or higher. Additives may be disposed in or on the hard cosmetic particles and delivered when the cosmetic particles are broken proximate a target such as the skin, hair or nails of a mammalian subject or another target. The transformable hard cosmetic particles permit the storage and shipment of intact cosmetic particles yet transform in situ to achieve the benefits of soft cosmetic particles.Type: GrantFiled: June 19, 2009Date of Patent: December 24, 2013Assignee: International Flora Technologies, Ltd.Inventors: Robert Kleiman, James H. Brown, Kelley Dwyer, James S. Brown
-
Patent number: 8609119Abstract: An active agent delivery and/or odor retentive composition including a surfactant and wax spheres formed from at least one of beeswax and soy wax and methods of use thereof. The composition is particularly useful in the cosmetics and medical industry for delivering/carrying a particular ingredient to one's skin, scalp or hair; for absorbing odor causing materials, such as fuel byproducts from a skin surface; and/or for providing exfoliating properties to the skin. The delivery system/carrying system is also useful in binding to certain nutritional materials, such as vitamins, minerals, antioxidants, and the like for ingestion and release into the body.Type: GrantFiled: July 11, 2012Date of Patent: December 17, 2013Assignee: UNIREM, Inc.Inventors: Raymond J. Tarasi, Gary W. Dalrymple, Peter Pugliese, Steven M. Pugliese
-
Publication number: 20130323320Abstract: A pH sensitive carrier which includes at least one pH sensitive compound selected from the group consisting of deoxycholic acid, cholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, C27 bile acid, glycodeoxycholic acid, glycyrrhizic acid, glycyrrhetinic acid and salts thereof, and at least one amphipathic substance selected from the group consisting of a phosphatidylcholine having 10 to 12 carbon atoms, a polyoxyethylene sorbitan monofatty acid ester having 12 to 18 carbon atoms, a sorbitan fatty acid ester having 16 to 18 carbon atoms, glycerol monooleate, glycerol dilaurate, glycerol distearate, glycerol dioleate, polyoxyethylene castor oil and ?-tocopherol, and which is capable of developing a membrane disruptive function promoting effect.Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventor: Naoki SAKAGUCHI
-
Publication number: 20130295170Abstract: Opiates, amphetamines, barbiturates and other drugs such as benzodiazepines are extensively abused or misused and are frequently the cause of death by overdosing. These drugs are also prone to oxidation and the final degradation products depend on the reactants and the reaction conditions. This invention describes the use of inactivating agents such as permanganates, peroxides, persulfates, bismuthates, periodates or other oxidants in a dosage form as an approach to minimize abuse and overdose. The product is designed such that the inactivating agent is released if there is an attempt to extract the drug from the formulation or in cases of overdose. Once released, the inactivating agent quickly degrades the drug and converts it into inactive compounds. Since the reactants (drug and inactivating agent) are incompatible in situations of normal drug usage, they are kept separated within the vehicle of the invention, but released for interaction in case of misuse.Type: ApplicationFiled: May 3, 2013Publication date: November 7, 2013Applicant: KYDES Pharmaceuticals LLCInventor: Stephen Dordunoo
-
Publication number: 20130280338Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: ApplicationFiled: April 17, 2013Publication date: October 24, 2013Inventors: Klaus WENING, Lutz BARNSCHEID, Sebastian SCHWIER
-
Publication number: 20130273172Abstract: The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: October 18, 2011Publication date: October 17, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
-
Patent number: 8557291Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: GrantFiled: May 27, 2009Date of Patent: October 15, 2013Assignee: Collegium Pharmaceutical, Inc.Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
-
Patent number: 8524280Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: GrantFiled: December 15, 2009Date of Patent: September 3, 2013Assignee: Banner Pharmacaps, Inc.Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Patent number: 8496969Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability.Type: GrantFiled: December 15, 2009Date of Patent: July 30, 2013Assignee: McNeil-PPC, Inc.Inventors: David Wynn, Nick Parikh
-
Patent number: 8491928Abstract: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.Type: GrantFiled: October 9, 2012Date of Patent: July 23, 2013Assignee: Galderma S.A.Inventors: Claire Mallard, Lara Baudonnet
-
Patent number: 8486043Abstract: Described here are unit dose containers, methods, and kits for treating asthma and other pulmonary conditions by nebulization. The unit doses of active agents are provided in a low volume formulation, which results in faster nebulization of the unit doses. The containers are also formed to minimize internal surface area so that effective re-dispersion of the active agents can be achieved while reducing adsorption to the walls of the containers.Type: GrantFiled: October 13, 2008Date of Patent: July 16, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Laxmi Iyer, Paul S. Uster
-
Patent number: 8461081Abstract: The invention relates to biocide compositions, comprising (a) at least one dialkylamide based on oleic and/or linoleic acid, and (b) at least one biocide. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. for an extended period.Type: GrantFiled: February 14, 2008Date of Patent: June 11, 2013Assignee: Cognis IP Management GmbHInventors: Joaquin Bigorra Llosas, Javier Raya, Bernd Fabry, Rainer Höfer, Benoit Abribat
-
Patent number: 8449917Abstract: The present invention concerns stable herbicidal solid compositions containing built-in adjuvant which exhibit improved herbicidal efficacy when used to control weeds in flooded rice paddies or fields.Type: GrantFiled: July 14, 2011Date of Patent: May 28, 2013Assignee: Dow AgroSciences, LLCInventors: Hiteshkumar Dave, Lei Liu, Raymond E. Boucher, Jr., David G. Ouse, Richard K. Mann, James M. Gifford, Yi-hsiou Huang, Åndrea C. McVeigh-Nelson, Martin C. Logan, Ashish Batra
-
Patent number: 8445027Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: June 3, 2011Date of Patent: May 21, 2013Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
-
Patent number: 8420125Abstract: A medical food and/or nutritional supplement for oral administration by mammals includes ?-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid.Type: GrantFiled: April 11, 2011Date of Patent: April 16, 2013Assignee: Response Scientific, Inc.Inventors: Gregory D. Webster, Emmanuel C. Opara
-
Patent number: 8383161Abstract: A pharmaceutically acceptable implant system comprising a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles having a radioopaque agent covalently attached to a plurality of the particles in the collection, with the radioopaque agent being present in the collection at a concentration of at least about 0.1% w/w. The implantable materials may be used, for instance, in an iatrogenic site and for fiducial marking.Type: GrantFiled: December 15, 2010Date of Patent: February 26, 2013Assignee: Incept, LLCInventors: Patrick Campbell, Amarpreet S. Sawhney
-
Publication number: 20130034612Abstract: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.Type: ApplicationFiled: October 9, 2012Publication date: February 7, 2013Applicant: GALDERMA S.A.Inventor: Galderma S.A.
-
Patent number: 8349294Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.Type: GrantFiled: December 14, 2010Date of Patent: January 8, 2013Assignee: Novartis AGInventors: Luis A Dellamary, Jean Riess, Ernest G Schutt, Jeffry G Weers, Thomas E Tarara
-
Patent number: 8349781Abstract: Fluid reservoirs which are based on polymer substrates and are capable of storing large amounts of fluids. The storage is reliable and the reemergence from the liquid reservoir is readily controllable, for example, via the temperature or via mechanical actions, to achieve retardation of the fluid release. Also, processes for producing such fluid reservoirs and also their use, for example in washing or cleaning compositions.Type: GrantFiled: December 19, 2011Date of Patent: January 8, 2013Assignee: Henkel AG & Co. KGaAInventors: Rene-Andres Artiga-Gonzalez, Hubert Harth, Mario Sturm, Frank Korber, Andreas Bauer
-
Publication number: 20120308663Abstract: The present invention relates to nanocapsules, including: a core essentially consisting of a fatty substance, which is liquid or semi-liquid at ambient temperature, and including a hydrophobic active principle and a diethylene glycol ether; an outer lipid shell which is solid at ambient temperature. The lipid nanocapsules of the invention are intended in particular for the manufacture of a drug.Type: ApplicationFiled: September 24, 2010Publication date: December 6, 2012Inventors: Emilie Roger, Frederic Lagarce, Jean-Pierre Benoit
-
Patent number: 8309138Abstract: A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 ?m or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble.Type: GrantFiled: February 15, 2008Date of Patent: November 13, 2012Assignee: ASKA Pharmaceutical Co., Ltd.Inventor: Yasunori Sato
-
Patent number: 8309139Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.Type: GrantFiled: April 18, 2006Date of Patent: November 13, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
-
Patent number: 8287907Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.Type: GrantFiled: November 10, 2006Date of Patent: October 16, 2012Assignee: Phares Pharmaceutical Research, N.V.Inventors: Steve Leigh, Matthew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
-
Patent number: 8268358Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: GrantFiled: January 20, 2011Date of Patent: September 18, 2012Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 8246999Abstract: The invention provides an article comprising, a mesoporous silicate matrix, such as a particle, having one or more pores; and one or more releasable caps obstructing one or more of the pores. The articles are useful as delivery vehicles for encapsulated agents such as therapeutic agents, polynucleotides, polypeptides and the like.Type: GrantFiled: March 26, 2009Date of Patent: August 21, 2012Assignee: Iowa State University Research Foundation, Inc.Inventors: Victor Shang-Yi Lin, Cheng-Yu Lai, Srdija Jeftinija, Dusan M. Jeftinija
-
Patent number: 8236333Abstract: An active agent delivery and/or odor retentive composition including a surfactant and wax spheres formed from at least one of beeswax and soy wax and methods of use thereof. The composition is particularly useful in the cosmetics and medical industry for delivering/carrying a particular ingredient to one's skin, scalp or hair; for absorbing odor causing materials, such as fuel byproducts from a skin surface; and/or for providing exfoliating properties to the skin. The delivery system/carrying system is also useful in binding to certain nutritional materials, such as vitamins, minerals, antioxidants, and the like for ingestion and release into the body.Type: GrantFiled: June 25, 2009Date of Patent: August 7, 2012Assignee: UNIREM, Inc.Inventors: Raymond J. Tarasi, Gary W. Dalrymple, Peter Pugliese, Steven M. Pugliese
-
Patent number: 8202512Abstract: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.Type: GrantFiled: August 4, 2011Date of Patent: June 19, 2012Inventor: Edward Larry McCleary
-
Patent number: 8168576Abstract: The present invention is related to an aqueous cleansing composition especially for keratin fibers such as human hair with excellent volume enhancing effect. First object of the present invention is a cleansing composition for hair comprising at least one surfactant selected from anionic, non-ionic and amphoteric ones and furthermore comprising at least one ethoxylated monoglyceride according to the general formula wherein R1 is a saturated or unsaturated and branched or straight alkyl chain with a chain length of 7 to 21 C atoms and x+y+z has a value of 3 to 200 and at least one (poly)propylene glycol according to the following formula wherein n has a value between 1 and 70.Type: GrantFiled: February 10, 2011Date of Patent: May 1, 2012Assignee: KAO Germany GmbHInventors: Martin Hoffmann, Diana Leukel-Schäfer
-
Patent number: 8168225Abstract: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is a dispersion of water, or aqueous extract or water dispersible material or water soluble material. The oil drops are encapsulated with a polymerisable material of natural origin. Such microcapsules are appropriated for spray-dry processes, to be used as dry powder, lyophilized, self-emulsifiable powder, gel, cream and any liquid form. The active compounds included in the microcapsules are beneficial to the health and other biological purposes.Type: GrantFiled: December 17, 2004Date of Patent: May 1, 2012Assignee: GAT Formulation GmbHInventors: Victor Casaña Giner, Miguel Gimeno Sierra, Barbara Gimeno Sierra, Martha Moser
-
Publication number: 20120093940Abstract: A medical food and/or nutritional supplement for oral administration by mammals includes ?-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid.Type: ApplicationFiled: April 11, 2011Publication date: April 19, 2012Applicant: RESPONSE SCIENTIFIC, INC.Inventors: Gregory D. Webster, Emmanuel C. Opara
-
Publication number: 20120093718Abstract: Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.Type: ApplicationFiled: March 29, 2007Publication date: April 19, 2012Applicants: SCITECH DEVELOPMENT, LLC, WAYNE STATE UNIVERSITYInventors: Ralph E. Parchment, Bhaskara R. Jasti, Ramesh R. Boinpally, Stephen E. Rose, Earle T. Holsapple
-
Patent number: 8142814Abstract: The present invention provides an apparatus and methods of producing particles that include a polymer, a wax and/or lipid and, optionally, a biologically active substance. In accordance with the methods of the invention, a load stock including a polymer, a wax and/or a lipid that is a solid at standard temperature and pressure and, optionally, a biologically active substance is provided. The load stock is contacted with a supercritical fluid to form a melt. The melt is contacted with a polar solvent under suitable conditions to form an emulsion. The emulsion is expanded across a pressure drop to form solid particles that include the load stock. The methods and apparatus facilitate the production of very small particles that have a narrow particle size distribution.Type: GrantFiled: January 30, 2004Date of Patent: March 27, 2012Assignee: Ferro CorporationInventors: Pratibhash Chattopadhyay, Boris Y. Shekunov, Jeffrey S. Seitzinger
-
Patent number: 8057823Abstract: The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine.Type: GrantFiled: March 2, 2001Date of Patent: November 15, 2011Assignees: Universite d'Angers, Ethypharm S.A.Inventors: Béatrice Heurtault, Patrick Saulnier, Jean-Pierre Benoit, Jacques-Emile Proust, Brigitte Pech, Joël Richard
-
Patent number: 8039015Abstract: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and then mixing that solution with the other wall-forming reactant, such as the Lewis acid. Various adjuvants may be included with the core component to contribute additional characteristics, such as enhancement of a controlled release characteristic or improved mechanical stability.Type: GrantFiled: December 7, 2005Date of Patent: October 18, 2011Inventor: Tycho J. Speaker
-
Publication number: 20110223257Abstract: The present invention relates to releasable fusogenic lipids and nanoparticle compositions containing the same for the delivery of oligonucleotides and methods of modulating gene expression using the same. In particular, this invention relates to releasable fusogenic lipids containing an imine linker and a zwitterionic moiety.Type: ApplicationFiled: November 17, 2009Publication date: September 15, 2011Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong Zhao, Weili Yan, Lianjun Shi, Dechun Wu, Maksim Royzen
-
Patent number: 7999005Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 25, 2008Date of Patent: August 16, 2011Assignee: Schering-Plough Animal Health CorporationInventors: Chung Shih, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Publication number: 20110182999Abstract: The present invention provides a ceramide dispersion which includes (1) ceramide-containing particles which contains a ceramide, which are dispersed in an aqueous phase as an oil-phase component, and which have a volume average particle diameter from 1 nm to 100 nm; and (2) a fatty acid component which is at least one of a fatty acid having a melting temperature not higher than 30° C. or a fatty acid salt; the amount of nonionic surfactant being 0 or not more than 0.1 times the total mass of the ceramide; the amount of an ionic surfactant other than the fatty acid component being 0 or less than 0.05 times the total mass of the ceramide; and the pH being from 6 to 8.Type: ApplicationFiled: September 30, 2009Publication date: July 28, 2011Applicant: FUJIFILM CORPORATIONInventors: Shinichiro Serizawa, Hisahiro Mori, Tomoko Tashiro, Yoshisada Nakamura, Jun Arakawa
-
Patent number: 7981911Abstract: Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.Type: GrantFiled: July 31, 2008Date of Patent: July 19, 2011Assignee: Abbott LaboratoriesInventors: Laman Alani, Soumojeet Ghosh
-
Publication number: 20110111044Abstract: The present invention is directed to nanoparticle compositions for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid.Type: ApplicationFiled: July 31, 2009Publication date: May 12, 2011Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong Zhao, Lianjun Shi